

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of
MAZARE, et al.

Examiner:

Art Unit: 1614

Application No.: 10/728,339

Filed: December 4, 2003

Title: **IMIDAZOLE DERIVATIVES AS FACTOR
Xa INHIBITORS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 14, 2005

Date of Deposit

Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.


- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The publication by KEMPTER, et al., Darstellung Von Heterocyclisch Substituierten Imidazolen Und Imidazo [2.1-b] Thiazolen, J. Prakt. Chem., 1971, 977-985 discloses:

The preparation of substituted imidazole and imidazo[2.1-b]thiazolene derivatives out of alpha-halogenketones and amidines. The general process described can be used for the preparation of the imidazole ring system.

Respectfully submitted,



Joseph Rossi, Reg. No. 31,403
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0085 US NP

| | | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------|---|----|---|-------------------------------|-------------------------|
| Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/728,339 |
| | | | | Filing Date | 12-04-2003 |
| | | | | First Named Inventor | NAZARÉ |
| | | | | Group Art Unit | 1614 |
| | | | | Examiner Name | |
| Sheet | 1 | of | 7 | Attorney Docket Number | DEAV2002/0085 - US - NP |

[illegible][illegible]

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|----|--------------------------|------------------------|-------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/728,339 | |
| | | | Filing Date | 12-04-2003 | |
| | | | First Named Inventor | NAZARÉ | |
| | | | Group Art Unit | 1614 | |
| | | | Examiner Name | | |
| Sheet | 2 | of | 7 | Attorney Docket Number | DEAV2002/0085 - US - NP |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | ABAD, et al., N-Multilabeled Adenine and Guanine Nucleosides. Syntheses Of [1,3,NH2-15N3]- and [2-13C-1,3,NH2-15N3]-Labeled Adenosine, Guanosine, 2'-Deoxyadenosine, and 2'-Deoxyguanosine, J. Org. Chem. 1999, 64, 6575-6582 | |
| | | ABARBRI, et al., Preparation Of New Polyfunctional Magnesiated Heterocycles Using A Chlorine-, Bromine-, or Iodine -Magnesium Exchange, J. Org. Chem. 2000, 65, 4618-4634 | |
| | | ALLEN, et al., Self-Assembled Helices From 2,2'-Biimidazoles, Chem. Eur. J. 2001, 7(3), 721-729 | |
| | | ANTHONY, et al., Design And In Vivo Analysis Of Potent Non-Thiol Inhibitors Of Farnesyl Protein Transferase, J. Med. Chem. 1999, 42, 3356-3368 | |
| | | ADANG, et al., A New Generation Of Orally Active Antithrombotics: Comparing Strategies In The GPIIb/IIIa, thrombin and Factor Xa areas, Drugs of the Future 2000, 25,369-383 | |
| | | BALDWIN, et al., Beta1-Selective Adrenoceptor Antagonists: Examples Of The 2-[4-{3-(Substituted Amino)-2-Hydroxypropoxyl} phenyl] Imidazole Class. 2, J. Med. Chem. 1986, 29, 1065-1080 | |
| | | BALDWIN, et al., 4-Trifluoromethylimidazoles And 5-(4-Pyridyl)-1,2,4-triazoles, New Classes Of Xanthine Oxidase Inhibitors, J. Med. Chem., 1975, 18(9), 895-900 | |
| | | BALDWIN, et al., Beta-Adrenergic Blocking Agents With Acute Antihypertensive Activity, J. Med. Chem., 1979, 22(6), 687-694 | |
| | | BRACKEEN, et al., An Efficient And Mild Synthesis Of Highly Substituted Imidazoles, Tetrahedron Lett. 1994, 1635-1638 | |
| | | BRESLOW, et al., Synthesis Of Some Polyimidazole Ligands Related To Zinc Enzymes, J. Am. Chem. Soc. 1983, 105, 5337-5342 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---------------------------------------------------------------------------------------------------|---|----|--------------------------|------------------------|-------------------------|
| Substitute for form 1449B/PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/728,339 | |
| | | | Filing Date | 12-04-2003 | |
| | | | First Named Inventor | NAZARÉ | |
| | | | Group Art Unit | 1614 | |
| | | | Examiner Name | | |
| Sheet | 3 | of | 7 | Attorney Docket Number | DEAV2002/0085 - US - NP |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | BUNDGAARD, et al., Novel Chemical Approaches in Prodrug Design, Drugs Of The Future, 16 (1991) 443-458 | |
| | | CHAN, et al., New N- and O-Arylations With Phenylboronic Acids And Cupric Acetate, Tetrahedron Letters 39 (1998) 2933-2936 | |
| | | CHENG Yung-Chi et al., Relationship Between the Inhibition Constant (K ₁) and the Concentration of Inhibitor which causes 50 per cent Inhibition (I ₅₀) of an Enzymatic Reaction, Biochem. Pharmacol., 1973, Vol. 22, pgs 3099-3108 | |
| | | COLLMAN, et al., Catalytic Activities of Cu(II) Complexes with Nitrogen-Chelating Bidentate Ligands in the Coupling of Imidazoles with Arylboronic Acids, J. Org. Chem.; 66; 2001; pp.7892-7897. | |
| | | COZZI, et al., Ethyl 2-[[5,6-Dihydro-7-(1H-Imidazol-1-yl)-2-Naphthalenyl] Oxy]-2-Methylpropanoate As A New Potent Oxyisobutyrate Hypolipidaemic With Unusual Features, Farmaco (1987) 42, 205-218 | |
| | | FLEISHER, et al., Improved Oral Drug Delivery: Solubility Limitations Overcome By The Use Of Prodrugs, Advanced Drug Delivery Reviews 19 (1996) 115-130 | |
| | | HARTWIG John F et al., Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand, J. Org. Chem., 1999, Vol. 64, pgs. 5575-5580 | |
| | | HARTWIG, John, Transition Metal Catalyzed Synthesis of Arylamines and Aryl Ethers from Aryl Halides and Triflates: Scope and Mechanism, Angew. Chem. 1998, 37, 2046-2067 | |
| | | HEINDEL, et al., Imidazole Carboxylates By A Claisen-Type Rearrangement Of Amidoxime-Propiolate Adducts, Tetrahedron Letters No. 1971, No. 18, pp. 1439-1440 | |
| | | JIMONET, et al., Bioisosteres Of 9-Carboxymethyl-4-Oxo-Imidazol[1,2-a]Indeno-[1,2-e]Pyrazin-2-Carboxylic Acid Derivatives. Progress Towards Selective, Potent In Vivo AMPA Antagonists With Longer Durations Of Action, Bioorganic & Medicinal Chemistry Letters 2001, 11, 127-132 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|----|--------------------------|------------------------|-------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/728,339 | |
| | | | Filing Date | 12-04-2003 | |
| | | | First Named Inventor | NAZARÉ | |
| | | | Group Art Unit | 1614 | |
| | | | Examiner Name | | |
| Sheet | 4 | of | 7 | Attorney Docket Number | DEAV2002/0085 - US - NP |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|----------------------------------------------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials [*] | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | JUDD, et al., Bromobenzofuran-Based Non-Peptide Antagonists Of Angiotensin II: GR13895, A Potent Antihypertensive Agent With High Oral Bioavailability, J. Med. Chem. 1994, 37, 3108-3120 | |
| | | KANG, et al., Copper-Catalyzed N-Arylation Of Aryl Iodides With Benzamides Or Nitrogen Heterocycles In The Presence Of Ethylenediamine, Synlett 2002, 3, 427-430 | |
| | | KAWASAKI, et al., Total Synthesis Of Nortopsentins A-D, Marine Alkaloids, Chem. Pharm. Bull. 44(10) 1831-1839 | |
| | | KEMPTER, et al., Darstellung Von Heterocyclisch Substituierten Imidazolen Und Imidazo [2.1-b] Thiazolen, J. Prakt. Chem., 1971, 977-985 | |
| | | KIM, et al, Preparation Of N(pi)-Alkyl- Histamine And Histidine Derivatives Through Efficient Alkylation Followed by Deprotection Using Activated Silica Gel, Tetrahedron Lett., 2000, 41, 10031-10034 | |
| | | KIMBONGUILA, et al. , On The Allyl Protection Of The Imidazole Ring Of Histidine, Tetrahedron, 1997, 53(37), 12525-12538 | |
| | | KLAPARS, et al., A General And Efficient Copper Catalyst For The Amidation Of Aryl Halides And the N-Arylation of Nitrogen Heterocycles, J. Am. Chem. Soc. 2001, 123, 7727-7729 | |
| | | KWONG, et al., Copper-Catalyzed Coupling Of Alkylamines And Aryl Iodides: An Efficient System Even In An Air Atmosphere, Organic Lett. 2002, 4 (4), 581-584 | |
| | | LAM, et al., New Aryl/Heteroaryl C-N Bond Cross-coupling Reactions Via Arylboronic Acid/Cupric Acetate Arylation, Tetrahedron Letters 39 (1998) 2941-2944 | |
| | | MANN Grace et al., Palladium-Catalyzed C-N(sp ²) Bond Formation: N-Arylation of Aromatic and Unsaturated Nitrogen and the Reductive Elimination Chemistry of Palladium Azolyl and Methyleneamido Complexes, J. Am. Chem. Soc., 1998, Vol. 120, pgs. 827-828 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|----|--------------------------|------------------------|-------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/728,339 | |
| | | | Filing Date | 12-04-2003 | |
| | | | First Named Inventor | NAZARÉ | |
| | | | Group Art Unit | 1614 | |
| | | | Examiner Name | | |
| Sheet | 5 | of | 7 | Attorney Docket Number | DEAV2002/0085 - US - NP |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|----------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | MATTHEWS, et al., Synthesis And Cardiotonic Activity Of Novel Biimidazoles, J. Med. Chem., 1990, 317-327 | |
| | | MEDERSKI Werner W K R et al., N-Aryl Heterocycles via Coupling Reactions with Arylboronic Acids, Tetrahedron, 1999, Vol. 55, pgs. 12757-12770 | |
| | | NICHOLS, et al., 1-(2,5-Dimethoxy-4-(Trifluoromethyl) Phenyl)-2-Aminopropane: A Potent Serotonin 5-HT _{2A/2C} Agonist, J. Med. Chem. 1994,37, 4336-4351 | |
| | | O'CONNELL, et al., Convenient Synthesis Of Methyl 1-Methyl-2,4-dibromo-5-imidazolecarboxylate, Synthesis 1988, 767-771 | |
| | | OHMORI, et al., Novel AMPA Receptor Antagonists: Synthesis and Structure-Activity Relationships of 1-Hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)-quinoxalinedione and Related Compounds, J. Med. Chem.; 39; 1996; pp.3971-3979. | |
| | | OLD David W et al., Efficient Palladium-Catalyzed N-Arylation of Indoles, Organic Letters, 2000, Vol. 2, No. 10, pgs. 1403-1406 | |
| | | OSTREIM James A et al., Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors via Combinatorial Chemistry, Biochemistry, 1998, Vol. 37, pgs. 1053-1059 | |
| | | PAUL, et al., Imidazo[1,5-d][1,2,4]Triazines as Potential Antiasthma Agents, J. Med. Chem. 1985, 28, 1704-1716 | |
| | | PIERCE, et al., Practical Synthesis And Regioselective Alkylation Of Methyl 4(5)-Pentafluoroethyl-2-Propylimidazole-5(4)-Carboxylate To Give DuP 532, A Potent Angiotensin II Antagonist, J. Org. Chem. 1993, 58, 4642-4645 | |
| | | QING, et al., First Synthesis Of Ortho-Trifluoromethylated Aryl Triflates, J. Chem Soc. Perkin Trans. I, 1997, 20, 3053-3057 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|----|--------------------------|------------------------|-------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/728,339 | |
| | | | Filing Date | 12-04-2003 | |
| | | | First Named Inventor | NAZARÉ | |
| | | | Group Art Unit | 1614 | |
| | | | Examiner Name | | |
| Sheet | 6 | of | 7 | Attorney Docket Number | DEAV2002/0085 - US - NP |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|----------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials [*] | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | SAKAMOTO, et al., Palladium-Catalyzed Cyanation Of Aryl and Heteroaryl Iodides With Copper (I) Cyanide, J. Chem. Soc. Perkin Trans I, 1999, 2323-2326 | |
| | | SEGEL Irwin H, Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems, Enzyme Kinetics, 1975, John Wiley & Sons, New York, pgs. 100-125 | |
| | | SHI, et al., A Practical Synthesis Of 2-Butyl-4-(5)-Chloro-5(4)-Hydroxymethyl-1H-Imidazole, Synthetic Communications, 1993, 23(18), 2623-2630 | |
| | | SHILCRAT, et al., A New Regioselective Synthesis Of 1,2,5-Trisubstituted 1H-Imidazoles And Its Application To The Development Of Eprosartan, J. Org. Chem. 1997, 62, 8449-8454 | |
| | | SU, et al., Methyl Chlorodifluoro Acetate A Convenient Trifluoromethylating Agent, Tetrahedron Lett. 1991, 32 (52), 7689-7690 | |
| | | TOKMAKOV Gennadii P et al., Rearrangement of 1-Arylindoles to 5H-Dibenz[b,f]azepines, Tetrahedron, 1995, Vol. 51, No. 7, pgs. 2091-2098 | |
| | | UMEMOTO, et al., Power And Structure-Variable Fluorinating Agents. The N-Fluoropyridinium Salt System, J. Am. Chem. Soc. 1990, 112, 8563-8575 | |
| | | UNANGST Paul C et al., Synthesis of Novel 1-Phenyl-1H-indole-2-carboxylic Acids. I. Utilization of Ullmann and Dieckmann Reactions for the Preparation of 3-Hydroxy, 3-Alkoxy, and 3-Alkyl Derivatives, J. Heterocyclic Chem., 1987, Vol. 24, pgs. 811-815 | |
| | | URATA, et al., A Novel And Convenient Method For Trifluoromethylation Of Organic Halides Using CF ₃ SiR ₃ /KF/Cu(I) System, Tetrahedron Lett. 1991, 32(1), 91-94 | |
| | | VERONESE, et al., One-Pot Synthesis of 2-Vinylimidazole Derivatives By Reaction Of Alpha-Hydroxyimino-Beta Dicarboxyl Compounds With Allylamine, Synthesis 1985, 300-302 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---|----|---|--------------------------|-------------------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/728,339 |
| | | | | Filing Date | 12-04-2003 |
| | | | | First Named Inventor | NAZARÉ |
| | | | | Group Art Unit | 1614 |
| | | | | Examiner Name | |
| Sheet | 7 | of | 7 | Attorney Docket Number | DEAV2002/0085 - US - NP |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | VERONESE, et al., Syntheses Of 2-Arylimidazole Derivatives Through Annelations Employing Benzylamines, J. Heterocyclic Chem., 17, 1723-1725 | |
| | | WEGNER, et al., Imidazole Aus Aldehyden, 1,2-Diketonen Und Fluessigem Ammoniak, Arch. Pharm, 1974, 492-495 English Abstract on Page 492. | |
| | | WOLFE, et al., Simple, Efficient Catalyst System For The Palladium-Catalyzed Amination Of Aryl Chlorides, Bromides, and Triflates, J. Org. Chem. 2000, 65, 1158-1174 | |
| | | YAMADA, et al., 2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent[d]imidazoles As A Novel Class Of Gastric H+/K+-ATPase Inhibitors, J. Med. Chem. 1996, 39, 596-604 | |
| | | YAMANAKA, et al., Syntheses Of Heteroaromatic Carboxylic Acids Closely Related To Fusaic Acid, Chem. Pharm. Bull. 1983 31(12) 4549-4553 | |
| | | YANG, et al., Palladium-Catalyzed Amination Of Aryl Halides And Sulfonates, J. Organomet. Chem. 1999, 576, 125 | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.